Dentsply Sirona: Can Transformation Rhetoric Finally Turn Into Sequential Improvement?

Dentsply Sirona Inc (XRAY) reports second-quarter 2026 earnings tomorrow, August 6th, before the market opens, with analysts expecting a sharp year-over-year decline in profitability. The dental equipment and consumables manufacturer faces a critical test as investors assess whether the company can stabilize margins and reverse a troubling pattern of earnings misses. With the stock trading near multi-year lows and analyst sentiment deteriorating, this report will determine whether XRAY can regain credibility or faces further downside.

Part 1: Earnings Preview

Dentsply Sirona is a leading manufacturer of dental equipment, consumables, and technology solutions, serving dental professionals and laboratories worldwide. The company operates through two primary segments: Essential Dental Solutions (consumables and small equipment) and Connected Technology Solutions (imaging systems and CAD/CAM equipment), making it a bellwether for the global dental industry.

Earnings Expectations: XRAY reports Q2 2026 results on August 6th before market open, with analysts expecting $0.36 per share on consensus revenue estimates around $880-890 million. The company most recently reported $0.27 per share for Q1 2026, missing the $0.28 consensus. Year-over-year, the outlook is concerning: the $0.36 estimate represents a 30.77% decline from the $0.52 reported in Q2 2025, reflecting significant margin pressure and operational challenges.

Key Themes Heading Into Earnings:

1. Margin Compression and Restructuring Execution: XRAY has been implementing a multi-year restructuring program to address cost inefficiencies and streamline operations. Investors will scrutinize whether these efforts are gaining traction or if margin headwinds continue to overwhelm cost savings. The sharp year-over-year EPS decline suggests the company is still struggling to offset inflationary pressures and volume softness.

2. Demand Environment and End-Market Recovery: The dental equipment market has faced headwinds from reduced patient visits and deferred capital spending by dental practices. Analysts are watching for signs of stabilization in equipment orders and consumables demand, particularly in North America and Europe, which represent the company's largest markets.

3. Guidance and Full-Year Outlook: With full-year 2026 estimates at $1.42 per share (down 11.25% year-over-year), any revision to guidance will be critical. The company's May update provided a range of $1.40-$1.50 for fiscal 2026, and investors need clarity on whether XRAY can achieve the upper end of that range or faces further pressure in the second half.

Analyst Commentary: Sentiment remains cautious heading into the print. The consensus has deteriorated over the past 90 days, with estimates drifting lower from $0.39 to $0.36 for Q2. Analysts cite persistent margin challenges and uncertainty around the pace of operational improvements. The wide estimate range ($0.31 to $0.42) reflects significant disagreement about near-term profitability, underscoring the lack of visibility into XRAY's turnaround trajectory.

Part 2: Historical Earnings Performance

Dentsply Sirona has struggled with consistency in recent quarters, posting three consecutive earnings misses after a brief period of outperformance. In Q1 2026, the company reported $0.27 per share against a $0.28 estimate, a 3.57% miss. This followed an identical miss in Q4 2025, where XRAY again delivered $0.27 versus $0.28 expected. The Q3 2025 report was particularly damaging, with the company posting $0.37 against a $0.45 consensus—a 17.78% shortfall that triggered a sharp selloff.

The pattern represents a marked deterioration from Q2 2025, when XRAY beat estimates by 4.00% with $0.52 versus $0.50 expected. That quarter now appears to have been an outlier rather than a turning point. The trend is clear: XRAY has missed estimates in three of the past four quarters, with an average miss of approximately 8% when it falls short. The consistency of recent disappointments has eroded investor confidence and contributed to the stock's underperformance, making tomorrow's report critical for re-establishing credibility.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Dentsply Sirona typically reports before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through or reversal dynamics.

XRAY exhibits high volatility around earnings, with an average absolute Day 0 move of 9.09% and Day +1 follow-through averaging 3.77%. The direction has been unpredictable: recent reports have triggered moves ranging from a catastrophic 28.02% decline (November 2024) to a 16.30% surge (May 2025). The May 2026 report produced a modest 1.52% gain on Day 0, but the February 2026 release saw a massive 15.50% rally on Day +1 despite minimal initial reaction, suggesting the market sometimes needs time to digest results.

The historical range data shows Day 0 intraday swings averaging 8.03%, indicating significant intraday volatility even when the close-to-close move is more modest. Investors should prepare for substantial price action: the stock has moved more than 10% on earnings day in half of the past eight reports, and follow-through moves exceeding 3% are common. Given the recent pattern of misses and the stock's depressed valuation, the risk of another sharp decline appears elevated if XRAY disappoints again.

Part 2.2: Options Market Expected Move

The options market is pricing a 10.61% expected move through the August 21st expiration, implying a range of $12.32 to $15.24. This is slightly above the historical Day 0 average move of 9.09% but well below the 3.77% average Day +1 follow-through, suggesting options traders are anticipating elevated but not extreme volatility. The expected move appears reasonable given recent history, though it may underestimate downside risk if XRAY delivers another significant miss similar to the 17.78% shortfall in Q3 2025.

Part 3: What Analysts Are Saying

Analyst sentiment on Dentsply Sirona is decidedly cautious, with a consensus rating of 3.11 (Hold) and an average price target of $13.59—essentially flat to the current price of $13.78. The rating breakdown shows limited conviction: 3 Strong Buys, 0 Moderate Buys, 13 Holds, 0 Moderate Sells, and 2 Strong Sells among 18 analysts covering the stock. The overwhelming Hold contingent reflects uncertainty about the turnaround timeline and reluctance to recommend the stock until operational improvements become more evident.

Sentiment has deteriorated over the past month, with one analyst downgrading from Hold to a more cautious stance. The average recommendation has slipped from 3.12 to 3.11, a subtle but meaningful shift given the already tepid consensus. Price targets range from a low of $9.00 to a high of $17.00, highlighting the wide dispersion of views on XRAY's prospects. The mean target of $13.59 implies just 1.4% downside from current levels, suggesting analysts see the stock as fairly valued at best, with limited upside until the company demonstrates sustained earnings improvement and margin expansion.

Part 4: Technical Picture

The Barchart Technical Opinion for XRAY has strengthened significantly heading into earnings, rising from 8% Buy a month ago to 40% Buy last week and now 56% Buy currently. This improvement reflects positive momentum as the stock has rallied from deeply oversold levels, though the signal remains in neutral territory rather than indicating strong bullish conviction.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates near-term momentum is decisively positive, with the stock in a short-term uptrend
• Medium-term (Hold): Neutral reading suggests the intermediate-term trend remains uncertain despite recent strength
• Long-term (50% Buy): Moderate buy signal reflects a longer-term trend that is improving but not yet firmly established

Trend Characteristics: The trend is characterized by Good strength and Average direction, suggesting momentum is building but the directional conviction remains moderate heading into this high-stakes earnings event.

The stock is trading at $13.78, positioned above its 10-day ($13.57), 20-day ($13.35), 50-day ($11.64), 100-day ($11.53), and 200-day ($11.82) moving averages, but below the 5-day ($13.86). This configuration shows XRAY has broken above all major moving averages after an extended period of weakness, with the 50-day, 100-day, and 200-day averages clustered in the $11.50-$11.80 range now serving as support.

The technical setup is cautiously constructive but fragile. XRAY has rallied approximately 18% from its lows near $11.50, reclaiming all key moving averages and generating positive momentum signals. However, the stock remains range-bound and vulnerable to a sharp reversal if earnings disappoint. The 10.61% expected move implies a potential retest of the $12.32 level on the downside, which would bring the stock back toward the 20-day moving average, or a breakout toward $15.24 on the upside. Given the pattern of recent misses and deteriorating analyst sentiment, the technical improvement appears tentative—a beat could trigger a sustained breakout, but another shortfall risks erasing recent gains and sending the stock back toward multi-year lows.